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ABSTRACT  We examined the clinical effect of Meropenem (MEPM) on severe pneumonia. 
We administered 3g of Meropenem daily to 20 patients with severe pneumonia: 8 community-
acquired pneumonia patients, 9 nursing and healthcare-associated pneumonia patients, and 
3 hospital-acquired pneumonia patients. It was effective in 15 of the 20 patients (75%): 8 of 
8 community-acquired pneumonia patients (100%), 6 of 9 nursing and healthcare-associated 
pneumonia patients (66.6%), and 1 of 3 hospital-acquired pneumonia patients (33.3%). 
Bacteriologically, 9 of a total of 10 strains (90%) were eradicated: 4 of 4 Streptococcus 
pneumoniae  strains, 2 of 2 methicillin-sensitive Staphlococcus aureus  strains, 1 of 2 
Enterococcus faecalis  strains, 1 of 1 Klebsiella pneumoniae  strain, and 1 of 1 Escherichia 
coli  strain. Hepatic dysfunction was observed as a side effect in 8 patients (40%). Based on 
the above, administration of MEPM daily 3 g is extremely effective for community-acquired 
pneumonia, while it appears ineffective in many cases of nursing and healthcare-associated 
pneumonia or hospital-acquired pneumonia, and results in hepatic dysfunction at a high 
frequency. (Accepted on January 8, 2013)
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INTRODUCTION
   Recently, the Japanese Ministry of Health 
recognized an increase in the daily dosage of MEPM 
from 1g to 3g for severe refractory infections, 
allowing coverage by the national health insurance 
system. To date, however, no investigations of the 
clinical effect of this treatment have been published. 
Therefore, we examined the clinical efficacy of a 
daily dose of 3g MEPM on severe pneumonia.
SUBJECTS AND METHODS
Subjects
   Subjects were 20 patients with severe pneumonia 
(8 community-acquired pneumonia, 9 nursing and 
healthcare-associated pneumonia, and 3 hospital-
acquired pneumonia) treated with a single 1g dose 
of MEPM, three times daily at Kawasaki Hospital, 
Kawasaki Medical School from June 2011 to June 
2012.
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Methods
   Underlying diseases, causative organisms, clinical 
efficacy, bacteriological efficacy, and side effects of 
these subjects were retrospectively examined. 
   Causative organisms were identified when 106/ml 
or greater was detected in the culture of purulent 
sputum. Effectiveness was determined in accordance 
with the criteria of the Japanese chemotherapy 
society1). This study was performed with the 
approval of the Kawasaki Medical School ethical 
committee. 
RESULTS
Cases (Table 1) 
   Subjects were 15 males and 5 females aged 
50 to 88 years (72.6±11.1 years) comprising 8 
community-acquired pneumonia2) patients and 9 
nursing and healthcare-associated pneumonia3) 
patients classified as severe according to the 
A-DROP sys t em and  3  hosp i t a l - acqu i r ed 
pneumonia4) patients classified as severe according 
to the I-ROAD system.  
Underlying diseases (Table 2)
   Underlying diseases included chronic obstructive 
pulmonary disease in 6, cerebrovascular disorder in 
3, Parkinson's disease in 3, bronchial asthma in 2, 
and lung cancer, bronchiectasis, pneumoconiosis, 
old pulmonary  tuberculosis, cerebral paralysis, and 
schizophrenia in 1 patient each.  
Causative organisms (Table 3)
   Causative organisms were identified in 10 of 20 
patients: 4 strains of Streptococcus pneumonia, 
2 strains of methicillin-sensitive Staphlococcus 
aureus, 2 strains of Enterococcus faecalis, and each 
1 strain of Klebsiella pneumoniae and Escherichia 
coli. 
Clinical efficacy (Table 4)
   Treatment with 3g/day MEPM was effective 
in 15 of a total of 20 patients (75%): 8 of 8 
community-acquired pneumonia patients (100%), 6 
of 9 nursing and healthcare associated pneumonia 
patients (66.6%), and 1 of 3 hospital- acquired 
patients(33.3%).
Bacteriological efficacy (Table 5) 
   Nine of a total of 10 strains (90%)  were 
eradicated : 4 of 4 strains of S.pneumoniae, 2 of 2 
Table 1. Subjects
No. of patients 20 ( M15,　F 5)
Age (years) 50 ～ 88 （72.6 ± 11.1）
Community – acquired pneumonia (severe) ８
Nursing and Healthcare – associated ９
　pneumonia (severe) ３
Hospital – acquired pneumonia (severe)
Table 2. Underlying diseases
Chronic obstructive pulmonary diseases ６
Cerebrovascular diseases ３
Parkinsonism ３
Bronchial asthma ２
Lung cancer １
Bronchiectasis １
Pneumoconiosis １
Old pulmonary tuberculosis １
Cerebral palsy １
Shizophrenia １
None １
Table 3. Causative organisms
Streptococcus pneumoniae ４
methicillin – sensitive Staphylococcus aureus ２
Enterococcus faecalis ２
Klebsiella pneumoniae １
Escherichia coli １
（10/20　patients）
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strains of MSSA, 1 of 2 strains of E.faecalis, 1 of 1 
strain of K. pneumoniae, and 1 of 1 strain of E. coli. 
Side effects (Table 6)
   Clinical adverse reaction included diarrhea in 
3 (6.0%). Abnormal laboratory findings included 
increased AST.ALT in 3, increased LDH in 2, 
increased AST.ALP, ALT, BUN, and ALP in 1 
patient each (9 patients: 45%). All were mild, and 
there were no patients who discontinued treatment 
or underwent treatment for side effects. 
DISCUSSION
   Administration of carbapenems is recommended 
for ICU patients with pneumonia in the JRS 
guidelines for the management of community-
acquired pneumonia in adults2), for pneumonia 
which requires hospitalization in the JRS guideline 
for nursing and healthcare-associated pneumonia3), 
and for all hospital-acquired pneumonia in the 
JRS guidelines for the management of hospital-
acquired pneumonia in adults4). It has been pointed 
out, however, that satisfactory clinical effect with 
carbapenems is elusive due to dosages that are 
smaller compared with those prescribed overseas5, 6).
   In overseas countries, daily administration 
of 3g imipenem/cilastatin (IPM/CS) or MEPM 
is recommended in severe infections, and its 
effectiveness has been reported in many cases. 
   Comparison of 3g IPM/CS daily and 3g MEPM 
daily in hospitalized patients with severe bacterial 
infections reported by Colardyn et al.7) showed an 
effective rate of 77% in the IPM/CS group and 76% 
in the MEPM group. In ICU patients with severe 
bacterial infections, Hartenauer et al.8) reported an 
effective rate of 85% in the IPM/CS group and 88% 
in the MEPM group. In ICU patients with serious 
bacterial infections, Verwaest et al.9) reported an 
effective rate of 69% in the IPM/CS group and 68% 
in the MEPM group. These results suggest that the 
clinical effect of 3g IPM/CS daily and 3g MEPM 
daily in severe infections is nearly equivalent. 
   Comparison of 3g MEPM daily and a combination 
of 6g ceftazidime (CAZ) daily plus 15mg/kg 
amikacin (AMK) daily in patients with serious 
bacterial infections reported by Mouton et al.10) 
Table 4. Clinical efficacy
Good Poor Efficacy rate(%)
Community – acquired pneumonia ８ ８ ０ 100.0
Nursing and Healthcare - associated pneumonia ９ ６ ３ 66.6
Hospital – acquired pneumonia ３ １ ２ 33.3
Total 20 15 ５ 75.0
Table 5. Bacteriological efficacy
Causative organisms No. of strains Eradicated Persisted Efficacy rate(%)
S. pneumoniae 4 4 100
MSSA 2 2 100
E. faecalis 2 1 1 50
K. pneumoniae 1 1 100
E. coli 1 1 100
Total 10 9 1 90
Table 6. Side effects
Clinical adverse reaction diarrhea 3 (3/20=6.0%)
Abnormal laboratory findings
AST ↑ .　ALT ↑ 3
LDH ↑ 2
AST ↑ .　AIP ↑ 1
ALT ↑ 1
BUN ↑ 1
AIP ↑ 1
(9/20=45%)
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showed an effective rate of 88% in MEPM group 
and 78% in a CAZ plus AMK group. In patients 
with ventilator-associated pneumonia, Lerma 
et al.11) reported an effective rate of 88% in the 
MEPM group and 78% in the CAZ plus AMK 
group. Furthermore, comparison of 3g MEPM daily 
and a combination of 6g CAZ daily plus 3mg/kg 
tobramycin (TOB) daily in patients with hospital-
acquired lower respiratory tract infections12) showed 
an effective rate of 89% in the MEPM group and 
72% in the CAZ plus TOB group. These results 
suggest that clinical effect of 3g MEPM daily in 
severe infections is more efficacious than that of a 
combination of CAZ plus aminoglycosides.
   While administration of 3g MEPM daily in severe 
refractory pneumonia has been allowed in Japan 
since 2011, no reports have been published to date 
describing the clinical effect of 3g MEPM daily in 
severe pneumonia. 
   Our results showed that 3g MEPM daily was 
effective in 15 of a total of 20 patients (75%): 8 of 
8 community-acquired pneumonia patients (100%), 
6 of 9 nursing and healthcare-associated pneumonia 
patients (66.6%), and 1 of 3 hospital-acquired 
pneumonia patients (33.3%). Prognosis of severe 
pneumonia was excellent in community-acquired 
pneumonia, extremely poor in hospital-acquired 
pneumonia, and intermediate in nursing and 
healthcare-associated pneumonia, which may reflect 
the state of the host. Even if high dose of MEMP is 
administered to a patient, if the state of the host is 
poor, the effect may be poor. 
   Hayashida et al.13) also reported a patient 
with bacterial meningitis who died in spite of 
administration of 3g MEMP daily.  
   Bacteriological efficacy included eradication of 9 
of a total of 10 strains(90%): 4 of 4 S. pneumoniae 
strains, 2 of 2 methicillin-sensitive S. aureus strains, 
1 of 2 E.faecalis strains, 1 of 1 K. pneumonia strain, 
and 1 of 1 E.coli strain, which reflects the excellent 
antibacterial effect of MEPM14). 
   Side effects included diarrhea in 3 (6.0%) and 
abnormal laboratory findings, mainly on hepatic 
dysfunction, in 9 (45%). Due to the high dose, 
the incidence of side effects is high, so that and it 
is necessary to pay particular attention to hepatic 
dysfunction. 
   It is concluded that administration of 3g MEPM 
daily was useful in community-acquired pneumonia, 
but ineffective in many cases of nursing and 
healthcare-associated pneumonia and hospital-
acquired pneumonia, and hepatic dysfunction may 
occur at a high frequency. Hereafter, it is necessary 
to examine whether 6g MEPM daily would be 
appropriate in nursing and healthcare-associated 
pneumonia and hospital-acquired pneumonia and 
whether switching to a therapeutic dose of 1g daily 
would be effective in preventing the onset of hepatic 
dysfunction when clinical symptoms are improved. 
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